Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

被引：0
|
作者：
Lynne Chepulis [1 ]
Mark Rodrigues [1 ]
Han Gan [2 ]
Rawiri Keenan [1 ]
Tim Kenealy [3 ]
Rinki Murphy [3 ]
Leanne Te Karu [4 ]
Jo Scott-Jones [3 ]
Penny Clark [5 ]
Allan Moffitt [6 ]
Sara Mustafa [7 ]
Ross Lawrenson [1 ]
Ryan Paul [1 ]
机构：
[1] University of Waikato,Waikato Medical Research Centre
[2] University of Waikato,School of Computing and Mathematical Scienes
[3] University of Auckland,Faculty of Medical and Health Sciences
[4] Health New Zealand / Te Whatu Ora Te Toka Tumai,undefined
[5] Midlands Health Network,undefined
[6] Northcare Medical Centre,undefined
[7] Procare Health Limited,undefined
[8] Health New Zealand / Te Whatu Ora Waikato,undefined
来源：
BMC Health Services Research | / 25卷 / 1期
关键词：
SGLT2i; GLP1RA; Type 2 diabetes; Health system access;
D O I：
10.1186/s12913-025-12601-3
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus : A Korean Real-World Post-Marketing Study
    Han, Jeonghee
    Lee, Woo Je
    Hur, Kyu Yeon
    Cho, Jae Hyoung
    Lee, Byung Wan
    Park, Cheol-Young
    DIABETES & METABOLISM JOURNAL, 2024, 48 (03) : 418 - 428
  • [42] Insulin initiation in Type 2 diabetic patients aged 75+in the real world
    Rodier, M
    Raccah, D
    Vaur, L
    Sert, C
    Chabrier, G
    Hanaire, H
    Fontaine, P
    Eschwege, E
    DIABETOLOGIA, 2004, 47 : A122 - A122
  • [43] Delays in Insulin Initiation among Patients with Type 2 Diabetes Mellitus in Southeast China: A Retrospective, Real-World Study
    Chen, Pin
    Ma, Xiao
    Chen, Hong
    Wang, Ke
    Zhou, Li
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 3059 - 3068
  • [44] REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY INITIATED WITH ANTIHYPERGLYCEMIC MEDICATIONS IN THE UNITED STATES
    Cai, J.
    Burudpakdee, C.
    Divino, V
    VALUE IN HEALTH, 2016, 19 (03) : A7 - A7
  • [45] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis
    Guerci, Bruno
    Giorgino, Francesco
    Garcia, Luis-Emilio
    Boye, Kristina
    Norrbacka, Kirsi
    Sapin, Helene
    Heitmann, Elke
    Lebrec, Jeremie
    Dib, Anne
    Federici, Marco O. Orsini
    DIABETES, 2021, 70
  • [46] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
    Boye, Kristina S.
    Sapin, Helene
    Garcia-Perez, Luis-Emilio
    Rosilio, Myriam
    Orsini Federici, Marco
    Heitmann, Elke
    Jung, Heike
    Aigner, Ulrich
    Guerci, Bruno
    Giorgino, Francesco
    Norrbacka, Kirsi
    DIABETES THERAPY, 2020, 11 (10) : 2383 - 2399
  • [47] Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
    Akshay B. Jain
    Steve Kanters
    Reena Khurana
    Jagoda Kissock
    Naomi Severin
    Sara G. Stafford
    Diabetes Therapy, 2021, 12 : 527 - 536
  • [48] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE
    Boye, K.
    Garcia-Perez, L. E.
    Sapin, H.
    Rosilio, M.
    Federici, Orsini M.
    Heitmann, E.
    Jung, H.
    Gentilella, R.
    Aigner, U.
    Guerci, B.
    Giorgino, F.
    Norrbacka, K.
    VALUE IN HEALTH, 2019, 22 : S593 - S593
  • [49] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
    Kristina S. Boye
    Hélène Sapin
    Luis-Emilio García-Pérez
    Myriam Rosilio
    Marco Orsini Federici
    Elke Heitmann
    Heike Jung
    Ulrich Aigner
    Bruno Guerci
    Francesco Giorgino
    Kirsi Norrbacka
    Diabetes Therapy, 2020, 11 : 2383 - 2399
  • [50] Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review
    Jared A. Houssarini
    Alan J. M. Brnabic
    Marwan Obaid
    Diabetes Therapy, 2022, 13 : 131 - 144
12345